Trials / Completed
CompletedNCT00480636
Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients
Fragmin Safety And Efficacy In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism And Extended Thromboprophylaxis In Cancer Patients In Slovakia (An Open, Prospective, Non-Comparative Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To collect postmarketing data about Fragmin safety and efficacy in the treatment of deep vein thrombosis with or without pulmonary embolism in cancer patients.
Detailed description
Method: consecutive patient sampling. Patients were (are) included in the study in consecutive manner if they fulfilled the inclusion criteria and any of the exclusion criteria were not present.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fragmin (dalteparin sodium ) | Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2007-05-31
- Last updated
- 2010-08-10
- Results posted
- 2010-08-10
Source: ClinicalTrials.gov record NCT00480636. Inclusion in this directory is not an endorsement.